Cytokinetics Inc (CYTK)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account
Sell

$30.00

Buy

$32.00

arrow-up$1.16 (+3.89%)

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Prices updated at 17 May 2025, 00:23 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Income statement

20172018201920202021202220232024
13m32m27m56m70m95m8m18m
-77m-58m-59m-41m-90m-146m-323m-321m
-113m-89m-99m-94m-186m-324m-496m-536m
-848.26-282.26-367.97-168.27-264.54-342.75-6,589.71-2,902.72
-128m-106m-122m-127m-215m-389m-526m-590m
-109m-83m-93m-87m-184m-332m-457m-493m
Sales, General and administrative36m31m40m53m97m178m174m215m
Interest expenses17m22m27m39m29m51m58m87m
Provision for income taxes--------
Operating expenses36m31m40m53m97m178m174m215m
Income before taxes-128m-106m-122m-127m-215m-389m-526m-590m
Net income available to common shareholders-128m-106m-122m-127m-215m-389m-526m-590m
-2.59-1.95-2.11-1.97-2.8-4.33-5.45-5.26
Net interest income-14m-17m-23m-33m-29m-40m-30m-35m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)-2.59-1.95-2.11-1.97-2.8-4.33-5.45-5.26
Free cash flow per share-0.0601-2.1094-1.5179-1.1051-1.1324-3.1191-4.6425-3.7963
Book value/share2.72490.9516-0.33582.10672.9366-0.1685-4.3173-0.1177
Debt equity ratio0.2892971.564626-1.2008241.045944---

Balance sheet

20172018201920202021202220232024
Current assets274m208m234m474m536m795m628m1,108m
Current liabilities32m22m26m31m72m85m103m180m
Total capital142m66m118m249m387m502m221m510m
Total debt32m42m136m139m270m749m756m789m
Total equity110m26m-11m113m244m-108m-386m-135m
Total non current liabilities--------
Loans32m40m129m136m143m610m607m646m
Total assets295m211m290m534m841m1,015m824m1,402m
Total liabilities--------
Cash and cash equivalents125m42m36m83m113m66m113m95m
Common stock54m55m59m71m85m95m102m118m

Cash flow

20172018201920202021202220232024
Cash at beginning of period67m125m42m36m83m113m67m113m
Cash dividends paid--------
-105m-102m-94m-2m-191m-311m-416m-400m
Investments (gains) losses-66m5m-75m-197m-148m-262m239m-553m
125m42m36m83m113m67m113m95m
Net income--------
-102m-101m-91m9m-143m-300m-414m-396m
-3m-889,000-3m-11m-49m-11m-1m-4m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.